| Design And Development Consultant – Combination Products |
Combination product as indicated by the Central of Federal Regulation CFR is expressed as a product that includes a medical device /or a medication/or a biologic consolidating any two of these classifications and at some point even every one of the three. The well-known term of combination product is the drug eluting stent (DES) which is a scaffold covered with a drug to prevent scar tissue from developing in the supply artery. Combination Products Project Development Process & Design Control
The Pharmaceutical organization which manufacturers the combination products are expected to implement the 21 CFR Part 210 and 211 and 21 CFR Part 820 for their manufacturing sites of the combination products. At the end of the design Phases, the DHF is compiled and shall be presented during the audits. The DMR shall be extracted from the DHF for the routine use and the tech transfer. The requirements mentioned in the DMR shall be used to create the DHR to demonstrate the routine production and compliances. As per the requirements of the ISO 13485:2016, the medical device file shall be established. Operon Strategist assists companies and medical device manufacturers by providing consultancy services that support the registration of drug-device Combination Products. We have experience with each constituent part and the GMP regulations that together form the basis for their development and manufacture: Drug (21 CFR 210/211), Device (21 CFR 820) and 21 CFR Combination Products (21 CFR Part 4).
Read More – Combination Products – Design And Development Consultant
Medical devices consultancy 